{"prompt": "['SPIMM-301 Version 4.0', '15 June 2018', 'a.', 'Abstinence, when it is in line with the preferred and usual lifestyle of the subject. Subject', 'agrees to use a highly effective method of contraception should they become sexually', 'active.', 'b. Relationships with male partners who have been surgically sterilized by vasectomy (the', 'vasectomy procedure must have been conducted at least 60 days prior to the Screening', 'Visit).', 'c.', 'Barrier method (e.g., condom or occlusive cap) with spermicidal foam/gel/film/cream', 'AND either hormonal contraception (oral, implanted, or injectable) or an intrauterine', 'device or system.', 'Note: Non-childbearing potential is defined as surgical sterilization (e.g., bilateral', 'oophorectomy, hysterectomy, or tubal ligation) or postmenopausal (defined as permanent', 'cessation of menstruation for at least 12 consecutive months prior to the Screening Visit).', '8. Male subjects with female partners of child-bearing potential must be willing to use a highly', 'effective method of contraception from the date they sign the ICF until 28 days after the last', 'dose of IMP.', 'A subject CANNOT meet any of the following Exclusion Criteria at the SPIMM-301 Baseline Visit', 'to be eligible for inclusion in the trial:', '1. Subject has myopathic signs and/or symptoms due to a neuropathic process (i.e. cerebellar', 'dysfunctions and peripheral neuropathies) or a gait problem that would interfere with the', '6MWT, in the opinion of the Investigator.', '2. Female subjects who are pregnant, planning to become pregnant, or breastfeeding/lactating.', '3. Walks < 100 meters or > 450 meters during the 6MWT at either the Screening Visit OR', 'Baseline Visit.', '4. At the Baseline Visit, the estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73 m\u00b2,', 'using the Screening Visit value with the Modification of Diet in Renal Disease (MDRD)', 'Study equation.', '5. Subject has undergone an in-patient hospitalization within the 30 days prior to the Baseline', 'Visit or has a planned hospitalization or a surgical procedure during the trial.', '6. Subject has clinically significant respiratory disease and/or cardiac disease (medical history', 'or current clinical findings), in the opinion of the Investigator, or prior interventional cardiac', 'procedure (e.g., cardiac catheterization, angioplasty/percutaneous coronary intervention,', 'balloon valvuloplasty, etc.) within 3 months of the Baseline Visit.', '7.', 'Subject has a pacemaker, implantable cardioverter-defibrillator or cardiac resynchronization', 'therapy device OR QTc elongation (using the correction factor utilized at the clinical', 'site) defined as a QTc >450 msec in male subjects and >480 msec in female subjects.', 'Note: At the initial electrocardiogram (ECG), if QTc exceeds these parameters, the ECG may', 'be repeated 2 more times (during the same visit), and the average of the 3 QTc values used to', \"determine the subject's eligibility.\", '8. ECG evidence of acute ischemia, atrial fibrillation, or active conduction system abnormalities', 'with the exception of any of the following:', 'a.', 'First degree AV-block', 'Stealth BioTherapeutics Inc.', 'CONFIDENTIAL', '8']['SPIMM-301 Version 4.0', '15 June 2018', 'b. Second degree AV-block Type 1 (Mobitz Type 1 / Wenckebach type)', 'c. Right bundle branch block', '9. Subject has severe vision impairment that, in the opinion of the Investigator, may interfere', 'with their ability to complete all trial requirements', '10. Subject has a seizure disorder that, in the opinion of the Investigator, may interfere with their', 'ability to complete all trial requirements.', '11. Active malignancy or any other cancer from which the subject has been disease-free for < 2', 'years.', '12. Subject has a solid organ transplant and/or is currently receiving treatment with therapy for', 'immunosuppression, in the opinion of the Investigator.', '13. Subject has been previously diagnosed with human immunodeficiency virus (HIV), hepatitis', 'B, or hepatitis C infection.', '14. Subject has a history of a systemic eosinophilic illness and/or an eosinophil count>1,000', 'cells x106/L at the Screening Visit.', '15. Subject is currently participating or has participated in an interventional clinical trial (i.e.,', 'investigational product or device, stem cell therapy, gene therapy) within 30 days of the', 'Baseline Visit; or is currently enrolled in a non-interventional clinical trial (except for', 'SPIMM-300) at the Baseline Visit which, in the opinion of the Investigator, may be', 'potentially confounding to the results of the current trial (e.g. exercise therapy trial).', '16. Subject has previously received elamipretide (MTP-131), for any reason.', '17. Subject has a history of active substance abuse during the year before the Baseline Visit, in', 'the opinion of the Investigator.', '18. Subject has any prior or current medical condition that, in the judgment of the Investigator,', 'would prevent the subject from safely participating in and/or completing all trial', 'requirements.', 'PART 2 Continuation Criteria', 'A subject must meet all of the following PART 2 Continuation Criteria at the Week 24 Visit in PART', '1 to be eligible for PART 2:', '1. Subjects must continue to be able and willing to adhere to the trial requirements.', '2. Subject is appropriate to continue in PART 2 (i.e. subject was compliant in PART 1), in the', 'opinion of the Investigator.', '3. Subject has not had a serious adverse event (SAE)/serious adverse device effect (SADE)', 'attributed to the elamipretide delivery system.', '4.', 'Subject has not permanently discontinued the elamipretide delivery system.', 'Investigational product, dosage and mode of administration:', 'Elamipretide injection will be supplied as a sterile 3.0 mL multidose glass cartridge containing 2.5', 'mL of elamipretide solution (elamipretide HCl [80 mg/mL], phosphate buffer, and benzyl alcohol) for', 'use with the elamipretide delivery system (the investigational medicinal product [IMP] [elamipretide', 'Stealth Bio Therapeutics Inc.', 'CONFIDENTIAL', '9']\n\n###\n\n", "completion": "END"}